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Abstract
We describe three recombinant engineered antibodies against three recombinant epitope
tags, constructed with divalent binding arms to recognize divalent epitopes and so achieve
high affinity and specificity. In two versions, an epitope is inserted in tandem into a protein of
interest, and a homodimeric antibody is constructed by fusing a high-affinity epitope-binding
domain to a human or mouse Fc domain. In a third, a heterodimeric antibody is constructed
by fusing two different epitope-binding domains which target two different binding sites in
GFP, to polarized Fc fragments. These antibody/epitope pairs have affinities in the low pico-
molar range and are useful tools for many antibody-based applications.
Introduction
Antibodies with good affinity and specificity are critical tools for biomedical research. As a recent
policy proposal points out, however, polyclonal antibodies are often neither very specific nor repro-
ducible, and monoclonal antibodies may also have poorly-defined specificity [1]. Recombinant
antibodies derived from a known coding sequence are much more reproducible and they can be
engineered to have higher affinity, specificity and stability. However some methods of improving
affinity, involving multiple rounds of mutation and selection, can be very time-consuming.
Bi-specific antibodies against a single protein (or protein complex) have been used to
increase effective affinity (avidity) and specificity through tandem binding [2] [3] [4]. Antibod-
ies are normally divalent, and tandem epitopes can exploit this to increase the avidity (Fig 1).
The rate for binding one epitope of a tandem pair, Cka (where ka is the concentration-
dependent on rate), is only doubled by the presence of two epitopes. However the rate from the
singly-bound to the doubly-bound state, kb, is hugely increased because the effective concentra-
tions of the second binding domain and epitope are determined by their close proximity rather
than by solution concentrations. Although there are detailed treatments of effective molarity
that incorporate a random-coil polymeric linker between epitopes [5], a simple calculation is
based on the volume accessible to the second epitope as determined by linker length. For
instance a particle constrained within a 20-nm radius has an effective molarity of about 50 μM.
At the same time, the unbinding rate is nearly unchanged, with a rate from doubly to singly
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bound, 2koff, that is just twice the monomeric off rate. Thus if one epitope unbinds, it is much
more likely to rebind before the second epitope unbinds. The effective dissociation constant
can be much lower, often in the picomolar range. This effect is more pronounced if the effective
radius is smaller, and less pronounced it the monomeric dissociation constant is higher.
Finally, it would not occur for off-target binding, where the inappropriate epitope is usually
not in tandem. Divalent binding thus increases both avidity and specificity.
We report the generation of three recombinant antibodies with high affinity for an engineered
epitope, using fusion proteins that include a small epitope-binding domain (EBD) and that
dimerize through standard antibody Fc domains. In one strategy two identical binding domains
independently bind to two identical epitopes placed in tandem with a short peptide linker. These
tandem epitopes may be inserted into a protein of interest for localization or immunoprecipita-
tion experiments. In a second strategy, two different EBDs bind to two different regions of a sin-
gle, untagged target protein, but are linked as a heterodimer by polarized Fc domains.
Previously reported bi-specific antibodies are generally against specific antigens rather than
engineered epitope tags [2] [3] [4]. These often use a flexible linker or a leucine zipper between
the two EBDs. The antibodies reported here use Fc domains from mouse or human to form
natural, covalent dimers. The Fc portion also helps to improve protein solubility and yield dur-
ing expression, and can be easily purified using protein A/G. It also serves as a handle to which
secondary antibodies bind and to which other secondary components (fluorescent dyes, gold
particles, etc.) may be conjugated.
Finally, we show that avidity depends on the length of the linker between the tandem epi-
topes, reflecting steric constraints in EBD binding that can reduce the theoretical improvement
in avidity.
Materials and Methods
Theory
The population of the unbound (P0), singly-bound (P1) and doubly-bound (P2) states of the
antibody can be calculated by the general form of rates for a three-state system:
P1 ¼ 1= 1þ
k12
k21
þ k10
k01
 
ð1Þ
P0 ¼
k10
k01
P1 ð2Þ
P2 ¼
k12
k21
P1 ð3Þ
Fig 1. Schematic of binding and unbinding for a divalent antibody and tandem epitope. A tandem
epitope (green) with variable linker length is bound in two steps by a divalent antibody (blue). If the proximity-
dependent rebinding rate (kb) is much larger than the monovalent unbinding rate (koff) then avidity is greatly
increased.
doi:10.1371/journal.pone.0150125.g001
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where k01 (= 2Cka in Fig 1) and k12 (= kb) are concentration-dependent binding rates with k01
depending on solution concentration and k12 depending on effective concentration calculated
from accessible volume. For these reagents, the volume has a radius of ~30 nm. k21 and k10 are
concentration-independent off rates and k12 is twice k10 to reﬂect the possibility of either half
of a tandem epitope unbinding. Fraction bound is (P1 + P2)/ (P0 + P1 + P2).
Construction of tandem epitope-tagged proteins
Tandem GCN4. Sequences encoding the 12-aa GCN peptide in tandem with a 10-aa or 19-aa
linker, together with the surrounding PCDH15 coding sequence, were synthesized and inserted
into protocadherin-15 (PCDH15) cDNA between EcoNI and EcoRV sites, resulting in a pro-
tein product with an insertion between EC domain 10 and EC domain 11.
THAP. Sequences encoding the high affinity peptide (HAP), or HAP in tandem with a
10-aa or 14-aa linker, together with the surrounding PCDH15 coding sequence, were synthe-
sized and inserted into protocadherin-15 (PCDH15) cDNA between EcoNI and EcoRV sites,
resulting in a protein product with an insertion between EC domains 10 and 11.
Construction of Fc-fusion antibodies
C11L34-Fc. A codon-optimized cDNA sequence coding for the C11L34 scFv was synthesized
and sub-cloned (using Gibson Assembly) into the EcoRI/BglII site of the pINFUSE vector
(Invivogen) containing the mouse IgG2b Fc, to create a homodimeric C11L34-Fc fusion.
anti-THAP. Codon-optimized cDNA sequences coding for α bungarotoxin (PDB: 1KL8_A)
were synthesized and sub-cloned into the EcoRI/BglII site of the pINFUSE vector containing
the human IgG2b Fc.
GBP1, GBP6-Fc. pINFUSE vectors containing the human IgG1 Fc were mutated to generate
heterodimer-forming constructs, pINFUSE_hIgG1_DD and pINFUSE_hIgG1_KK [6].
Codon optimized cDNA sequences coding for GBP1 or GBP6 were synthesized and sub-
cloned into the EcoRI/BglII site containing the human IgG1 Fc.
Production and purification were performed by the University of North Carolina at Chapel
Hill Protein Expression and Purification Core Facility. Briefly, HEK293f cells (Invitrogen) were
transiently transfected (using PEI) with these pINFUSE plasmids. The cells were grown in
Freestyle 293 media (Gibco) at 37°C/8%CO2 in suspension culture for 7–10 days. The superna-
tant was harvested, and secreted Fc-fusion proteins were purified using a 1 ml rProtein A
HiTrap column (GE Healthcare) on an AKTA ExPress FPLC (GE Healthcare). Eluted fractions
from the affinity purification were pooled and the integrity of the proteins was verified by
reducing and non-reducing SDS-PAGE analysis (Novex-Invitrogen).
Western blot
From HEK293 cells transfected (Effectene, Qiagen) with PCDH15, PCDH15-HAP,
PCDH15-THAP, PCDH15-GCN, PCDH15-2XGCN_L10, and PCDH15-2XGCN_L19
cDNAs, total cell lysates were prepared and insoluble matter pelleted. Equal amounts of the
supernatant were separated by 3–7% Tris-acetate SDS-PAGE (Novex-Invitrogen). Separated
proteins were transferred to PVDF membranes (Immobilon FL, Millipore). For subsequent
steps, we followed the protocol from Li-COR Biosciences, with overnight primary antibody
incubation at 4°C (Rabbit anti-PCDH15, 0.5 μg/ml; anti-THAP, 0.01 μg/ml) and secondary
antibody incubation at room temperature for 30 min. The rabbit anti-PCDH15 antibody was
generated using the same synthesized peptide used by Kazmierczak et al.[7] to produce the
PB811 antibody.
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Fluorescence imaging and analysis
RPMI-2650 cells (ATCC #CCL-30) were transfected (Effectene, Qiagen) with the tagged
PCDH15 construct. 24–48 hours after transfection, live cells were incubated for 30 min at 4°C
with anti-tag antibodies at a range of concentrations. We used C11L34-Fc, 10 pM– 30 nM;
anti-THAP, 6 pM– 12 nM; BTX-biotin (Biotium), 1–150 nM. Cells were washed with PBS,
fixed with 4% formaldehyde, washed with PBS, then blocked with PBS containing 10% normal
goat serum (NGS) and 0.2% saponin. In some experiments they were then incubated with anti-
PCDH15 antibody (using a single, fixed concentration: rabbit anti-PCDH15, 5 μg/ml). Alterna-
tively, the transfected cells were fixed, blocked, and then incubated with both the anti-tag anti-
bodies (using a range of concentrations) and anti-PCDH15 antibody (using a single, fixed
concentration: rabbit anti-PCDH15, 5 μg/ml). CHO cells were transfected with TMC1_EGFP
(a construct that expresses a fusion protein of EGFP and the transmembrane protein TMC1),
fixed and blocked as above, and labeled with rabbit anti-GFP (A-11122, Life Technologies, at
5ug/ml) and/or GBP1_6 (100 pM). Cells were then incubated with secondary reagents (Jackson
ImmunoResearch, goat anti-rabbit/Alexa 647, goat anti-human Fc/Cy3, and streptavidin/
Alexa 488), then washed, mounted, and imaged with an Olympus FV1000 confocal microscope
equipped with a 60x, 1.42 NA oil objective.
For apparent affinity calculation, 5–10 thin processes from 10–20 cells were selected for each
concentration using an algorithm developed by Dr. Tiao Xie at the HMS Image and Data Analy-
sis Core. To avoid signal saturation, only thin processes of the cells were used for quantitative
analysis. The ratio of the fluorescence signal generated by the anti-tag antibody and the anti-
PCDH15 antibody was calculated and averaged for each concentration of anti-tag antibody, as in
McCann et al [8], Pollard [9], and Hulme & Trevethick [10]. The ratios were plotted against con-
centration of anti-tag antibody using GraphPad Prism software and fitted by a single exponential
binding curve. From the binding curve, Kd and n were calculated using the following equation:
Ymin þ ðYmax  YminÞð
Lt
n
Ltn þ Kd
Þ ð4Þ
where Ymin is the ratio of ﬂuorescent signals (anti-tag/anti-PCDH15) in the absence of anti-tag
antibody, Ymax is the ratio at saturating concentrations of anti-tag antibody, Lt is the total concen-
tration of anti-tag antibodies titrated and n is the Hill coefﬁcient. The calculation was done by
Prism software.
Surface plasmon resonance analysis
SPR experiments were carried out at the University of Maryland School of Medicine Biacore
Facility, using a Biacore 3000 instrument (GE Healthcare). Flow cells of CM5 sensor chips (GE
Healthcare) were coupled with goat anti-human IgG to 5,000 to 22,000 RU using amine cou-
pling chemistry, as described by the manufacturer. The coupling was performed by injecting
30 μg/ml of goat anti-human IgG (Jackson ImmunoResearch) in 10 mM sodium acetate pH
5.0 (GE Healthcare). All anti-tag antibodies with human Fc were captured by goat anti-human
IgG to a CM5 chip. HBS-EP buffer (10 mMHEPES, 150 mMNaCl, 3 mM EDTA, 0.05% sur-
factant P20; GE Healthcare) was used as running buffer and dilution buffer. Aliquots of 100 μl
containing concentrations of each of the peptides (HAP, THAP_10, THAP_14) or recombi-
nant EGFP (Kerafast, FR0008), ranging from 0 to 10 nM, were injected over immobilized anti-
THAP or GBPs (with human Fc) at a flow rate of 50 μl/min at 25°C. Regeneration of the sur-
faces was done using injections of 10 mM glycine, pH 1.75, followed by HBS-EP at pH 7.4. In
all experiments, data were zero adjusted and the reference cell subtracted. Data were evaluated
using BIAevaluation 4.1 software (GE Healthcare).
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Single-molecule pull-down
The monomeric YFP (mYFP) construct was described previously [11]. The THAP tag was cre-
ated by annealing two complementary oligos and inserted into the pCDNA3.1+ vector (Invi-
trogen). The mYFP-His6 cassette from the original mYFP construct was subcloned into
pCDNA3.1-THAP to generate the THAP-mYFP-His6 construct and was transiently expressed
in HEK293 cells. Cells were harvested into lysis buffer (10 mM Tris at pH 7.9, 0.1% Triton X-
100, 150 mMNaCl, 2 mM EDTA, 5 μg/ml pepstatin, 1 mM PMSF, 1 mMNaF, and 1 mM
Na3VO4) and lysates were serially diluted, then applied for single-molecule pull-down analysis.
THAP-mYFP-His6 from lysate was immobilized on biotinylated anti-His (Qiagen), anti-
THAP, anti-EGFP (Rockland Immunochemicals) or GBP1_6-Fc, or on biotinylated anti-HA
as a negative control.
Anti-THAP and GBP1+6-Fc were labeled with EZ-Link Hydrazide-PEG4-Biotins (Thermo
Scientific) according to the manufacturer’s manual. The concentration of the biotinylated pro-
teins and biotin incorporation were determined by a Nanodrop spectrophotometer (Thermo
Scientific).
EGFR was amplified by PCR from a plasmid containing full length EGFR coding sequence
(kindly provided by Dr. Colleen Sweeney, UCDMC) and inserted into the mYFP construct.
The EGFR-mYFP construct was transiently expressed in HEK293 and CHO cells with different
DNA amounts as indicated for 12 hours in serum-free medium, and then treated with or with-
out 10 mM EGF ligand immediately before harvesting cells. Cells were harvested into lysis
buffer (10 mM Tris pH 7.9, 0.1% n-dodecyl-D-maltoside (DDM), 150 mMNaCl, 2 mM
EDTA, 5 μg/ml pepstatin, 1 mM PMSF, 1 mM NaF, 1 mM Na3VO4) and lysates were applied
for single-molecule pull-down analysis. Proteins were immobilized on biotinylated GBP1+6-Fc
or anti-GFP antibody.
Results
TandemGCN4 epitope and single-chain antibody fragment/Fc fusion
We first developed an antibody/epitope pair using a peptide antigen derived from the leucine
zipper domain of the yeast transcription factor GCN4. Berger et al. (1999) [12] [13] raised anti-
bodies to a 33-amino-acid GCN4 peptide and used directed, in vitro evolution to derive a sin-
gle-chain antibody fragment (scFv; clone C11L34) with high affinity. To further increase
avidity, we engineered a divalent antibody with the C11L34 scFv fused to a mouse Fc fragment
(Fig 2A; two related constructions in Fig 2B and 2C are discussed below).
We then made a tandem epitope with two copies of a 12-amino-acid fragment of the original
peptide (AHLENEVARLKK; termed GCN), separated by either a 10- or 19-amino-acid linker.
We tagged a membrane protein of interest, mouse protocadherin-15 (PCDH15), by inserting
either a single or tandem GCN epitope into its extracellular domain. The tagged PCDH15 was
expressed in RPMI 2650 cells, and fixed or unfixed cells were labeled with a conventional anti-
body to PCDH15 at a fixed concentration and with the C11L34-Fc fusion antibody at variable
concentration. We then plotted the ratio of C11L34-Fc antibody fluorescence to anti-PCDH15
fluorescence to calculate avidity. The Kd of C11L34-Fc for a single GCN epitope was about 900
pM (Fig 3A). The avidity for a tandem GCN epitope was about the same, when the linker was 10
amino acids. With a longer 19-aa linker, however, the effective Kd was ~60 pM, so the shorter
linker apparently prevented the second C11L34 scFv from reaching the second GCN.
We also tested the same constructs with immunoblots (Fig 3B; S3 Fig). As with immunocy-
tochemistry, the tandem epitope with 19-aa linker markedly increased binding compared to
the single epitope or the tandem epitope with shorter linker. In general, the avidity was
High Affinity and Specificity Engineered Antibodies against Recombinant Tags
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increased by more than an order of magnitude by dimerizing the C11L34 EBD and by con-
structing a tandem epitope with the appropriate linker.
Dimerizing EBDs with Fc’s has several advantages in addition to avidity: Fc fusion proteins
can be recombinantly expressed, with good protein yield and solubility. Also, the Fc fragment
is a convenient handle, which enables signal amplification (through secondary antibodies), and
chemical conjugation (to fluorophores, magnetic beads, gold particles, surface immobilization,
etc.) [14]. Finally, by using Fc fragments from different IgG classes and different species, a vari-
ety of reagents with the same EBDs can be generated, enabling great flexibility in imaging
experiments where multiple components are studied.
THAP/anti-THAP system
Additional performance can be gained by using naturally-occurring peptide/ligand pairs as a
starting point for a tandem epitope/antibody system, because they can be smaller and more sta-
ble. One such pair is α-bungarotoxin (BTX) and the peptide to which it binds. Bungarotoxin,
isolated from the snake Bungarus multicinctus, is a 74-amino-acid protein that binds the acetyl-
choline receptor (AChR) of skeletal muscle with high affinity and specificity [15]. The BTX
binding site on the AChR is an antiparallel β-hairpin structure of about 13 amino acids.
Although BTX has been used with the epitope derived from its binding site in the AChR, short
peptide sequences with higher affinity for BTX have been isolated [16] [17]. One of these pep-
tides, a 13-amino acid peptide (WRYYESSLEPYPD) called high affinity peptide (HAP), has
the highest affinity of those identified—about 2 nM. It forms an antiparallel β-hairpin structure
like the native ligand [16]. HAP, in combination with fluorophore-conjugated BTX, has been
used to label a variety of proteins in both fixed and live cells [8, 18].
Although the HAP/BTX is a useful system for cellular imaging, its affinity and specificity
are not ideal. The apparent affinity of the HAP/BTX interaction in real imaging experiments is
Fig 2. Strategy for designing high-affinity antibodies. (A) Schematic of the scFv C11L34-Fc fusion binding to a tandemGCN epitope. The recombinant
antibody has identical Fc regions and is homodimeric. (B) THAP and anti-THAP. Bungarotoxin (BTX) replaces the variable region. (C) Recombinant bi-
specific antibody to EGFP, created by different mutation of each Fc region to force heterodimeric binding. Each half of the dimer incorporates a nanobody
(GBP1 or GBP2) targeting different regions of EGFP.
doi:10.1371/journal.pone.0150125.g002
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Fig 3. Performance of homodimeric antibodies with tandem epitopes. (A) Binding of recombinant C11L34 antibody to a single or tandemGCN epitope
placed within the PCDH15 sequence and expressed in RPMI 2650 cells. Binding was normalized to the signal of an anti-PCDH15 antibody. The binding to
the tandem epitope was about 15x better, if the linker was 19 amino acids (green line) but not if the linker was shorter (magenta). (B) Immunoblots of cell
extracts showing much stronger binding to the tandem epitope with longer linker. Lysates from HEK cells expressing PCDH15 with different tags were run on
two identical gels; one was probed with the divalent C11L34 anti-GCN at a fixed concentration and one with anti-PCDH15 as a loading control. Full sized
immunoblots are in S3 Fig. (C) Binding of recombinant anti-THAP antibody or biotinylated BTX to a single or tandem HAP epitope placed within the PCDH15
sequence, normalized to the anti-PCDH15 signal. Anti-THAP avidity for the THAP tag was about 7X better than to the single HAP tag. (D) Immunoblots of cell
extracts showing much stronger binding to the tandem epitope than to the single HAP. Protocol as in (B). Lower panel shows the binding to the tagged
PCDH15 by anti-THAP relative to anti-PCDH15. Full sized immunoblots are in S4 Fig. (E) Biacore surface plasmon resonance analysis of binding between
the recombinant antibodies to HAP or THAP peptides. One antibody (anti-THAP; shown as BTX:BTX) contained symmetric BTX binding domains, while
another (BTX:con) was asymmetric with one arm containing BTX and the other an irrelevant control binding domain. The THAP peptide showed higher
affinity, but it was substantially higher only for the anti-THAP antibody, and only when the linker length was 10 rather than 14 amino acids. Representative
traces are in S1 Fig. Measured rate constants and dissociation constants are in S1 Table. (F) Single-molecule pull-down assay. Cell lysates containing
monomeric YFP tagged with THAP and 6xHis were applied at different dilutions to slides with immobilized anti-His or anti-THAP antibodies, or anti-HA as a
negative control. Insets showmolecules pulled down. Full immunoblots for panels B and D are shown in S3 and S4 Figs.
doi:10.1371/journal.pone.0150125.g003
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14–60 nM rather than the 2 nM of biochemical experiments [8, 18], with a significant back-
ground. We suspect the loss of affinity and specificity in imaging experiments is due in part to
the conjugation of fluorophores to BTX through its primary amine groups (lysine side chains
and N terminus), which may inhibit binding. In addition, there is no further signal amplifica-
tion with labeled toxin, as there can be with secondary antibodies. The lack of signal amplifica-
tion makes it difficult to use the HAP/BTX system in demanding situations such as single
molecule imaging, which require higher signal-to-noise ratio and specificity. The amplification
issue can be addressed by conjugating BTX to biotin and using streptavidin as a secondary
detection step. However, the reduced affinity/specificity issue remains.
We therefore made the HAP tag divalent by placing two HAPs in tandem (THAP) with a
flexible linker of 10 or 14 amino acids. The linker length was based on the crystal structure of
BTX/HAP [19], assuming that each amino acid can extend about 0.3 nm. We made the BTX
divalent by fusing it with the Fc portion of human IgG2b, which naturally dimerizes through
multiple disulfide bonds [14], to create a divalent antibody we term anti-THAP (Fig 2B).
We again used immunofluorescence to compare the avidity of HAP/BTX and THAP/anti-
THAP. We inserted HAP and THAP sequences into the extracellular domain of PCDH15 and
transiently expressed the tagged proteins in RPMI 2650 cells. Immunofluorescence of the
THAP reagent was compared to that of a fixed concentration of anti-PCDH15 (see METH-
ODS). As shown in Fig 3C, biotinylated BTX binding to the tandem THAP had a dissociation
constant of ~10 nM in these conditions. Anti-THAP binding to PCDH15 with a single HAP
had a dissociation constant of ~0.4 nM. As both are monomeric binding reactions, the better
affinity of BTX when fused to Fc (anti-THAP) may result from a BTX binding surface unmodi-
fied by biotin. The effective affinity of the dimeric THAP/anti-THAP pair, however, is about
70pM, about 7-fold higher than the HAP/anti-THAP and 500-fold higher than the HAP/BTX.
We stained the cells under live and fixed conditions, which give similar results.
We also tried the THAP/anti-THAP pair in immunoblots (Fig 3D; S4 Fig). The THAP tag
in PCDH15 generated a signal that is about 30-fold that of HAP when probed with anti-
THAP, highlighting the power of divalent interaction.
To directly measure the affinity between THAP and anti-THAP, we performed surface plas-
mon resonance analysis, using THAP peptides with different linkers (Fig 3E; S1 Fig; S1 Table).
The interaction of anti-THAP with THAP incorporating a 14-aa linker (THAP_L14) has an
effective dissociation constant of ~430 pM, and interaction with THAP_L10 has an effective
dissociation constant of ~100 pM, similar to that obtained with the immunofluorescence assay
and about 20 fold lower than the monovalent HAP/BTX interaction of ~2000 pM. With this
tandem epitope as well, linker length is an important determinant of avidity.
Finally, we used a single molecule pull-down assay [11] to analyze THAP/anti-THAP inter-
action (Fig 3F). We compared THAP/anti-THAP with the commonly used 6XHis /anti-His
system. Different antibodies with same concentration were immobilized on the surface of
microscopy slides, and cell lysate containing a fusion protein with both THAP and 6XHis tags
was serially diluted and applied to the slides for counting individual proteins. With the same
diluted cell lysates, anti-THAP pulled down much more fusion protein than anti-His. Anti-
THAP is about 16 times more effective than anti-His antibody in this assay.
GBP1+6-Fc: a bi-specific antibody against GFP
The THAP/anti-THAP system requires engineering a THAP tag into a protein. Often a high-
affinity antibody is needed for a native protein. We extended the bivalent concept to create a
system in which two native epitopes close to each other in a protein are recognized by a bi-spe-
cific reagent with different EBPs.
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Sera of certain species contain both conventional IgGs as well as unusual single chain anti-
bodies (sdAb)—sometime termed nanobodies. These species include camels, dromedaries, lla-
mas and alpacas, and so the sdAbs have also been termed camelid antibodies. SdAbs are small,
have good solubility and have good thermal stability. The variable domains of sdAbs (VH; 12–
15 kD) can be expressed recombinantly [20].
Fc fusion proteins can be made heteromeric by engineering the CH3 domain in the Fc seg-
ment[6]. We reasoned that if two nanobodies bind independently to two different parts of the
protein, we could generate a heteromeric, bi-specific nanobody-Fc fusion protein. The bi-spe-
cific nanobody-Fc should have better specificity and avidity than conventional IgGs, because
there would be two arms binding the same protein in different places, in the same way that the
divalent anti-THAP binds to two HAP epitopes in tandem. Although bi-specific (“bi-parato-
pic”) nanobodies have been reported that have improved affinity when the two nanobodies are
connected with a flexible linker[3], lack of a “handle” (for purification, chemical conjugation
and signal amplification) limits their use in many antibody-based applications.
Several nanobodies, GBP1-7, against enhanced green fluorescent protein (EGFP) have been
generated and characterized [21]. Of these, GBP1 and GBP6 bind to EGFP independently [22].
We generated a heterodimeric Fc fusion protein, GBP1+6-Fc, by separately fusing GBP1 and
GBP6 to oppositely polarized Fc fragments that can only bind to each other and not homodi-
merically (Fig 2C). We used a Biacore-3000 analyzer to measure interaction between EGFP
and GBP1-Fc, GBP6-Fc, and GBP1+6-Fc (Fig 4A; S2 Fig; S1 Table). GBP1+6-Fc binds to
EGFP with an effective dissociation constant of 32 pM, about 3-fold less than that of GBP1-Fc
and 18-fold less than reported for bacterially expressed GBP1 [21]. The difference in measured
affinity between bacterially expressed GBP1 and GBP1-Fc is probably due to differences in
their conjugation to the chip surface: the bacterially expressed GBP1 was conjugated using
amine-based conjugation [21], which could interfere with its interaction with EGFP, whereas
the GBP1-Fc was conjugated through the Fc portion (using an anti-human Fc antibody),
which left the GBP1 intact.
We then evaluated the specificity of GBP1+6-Fc in immunostaining experiments. In fixed
CHO cells expressing a membrane protein of the endoplasmic reticulum (TMC1) tagged with
EGFP or mCherry, GBP1+6-Fc labeled the EGFP-, but not mCherry-tagged protein. Com-
pared to a good commercially available anti-GFP antibody (Life Technologies A-11122), GBP1
+6-Fc produced brighter signal with less background (Fig 4B). In addition, GBP1+6-Fc labeled
cells with very low EGFP expression (Fig 4C). Because GBP1 increases the EGFP signal by sev-
eral fold upon binding to the fluorescent protein [21], the signal-to-noise ratio of GBP1+6-Fc
could be even higher.
We also compared GBP1+6-Fc with the anti-GFP antibody in single molecule pull-down
experiments. Because GFP and variants such as YFP share structure and most sequence, GBP1
+6-Fc should bind all of them. Indeed, GBP1+6-Fc is about 6 times more sensitive than anti-
GFP antibody in pulling down the same number of YFP fusion proteins (Fig 4D).
To further explore the efficacy of GBP1+6-Fc, we used this antibody to detect the dynamics
of epidermal growth factor receptor (EGFR) before and after ligand binding. EGF binds to the
monomeric form of EGFR and induces EGFR dimerization for signaling transduction [23].
However, the existence of preformed dimeric EGFR in quiescent cells is controversial.
Although ligand-independent dimerization was reported in cancer or transfected cells with
large amounts of receptor [24] [25], protein over-expression might lead to the formation of
aggregates [26] [27], and artificial formation of dimeric EGFR. We therefore transfected YFP-
tagged EGFR at very low levels (50 ng/106 cells, 10–40 times less than normal), which was close
to the physiological condition in normal cells but fell below the detection limits of anti-GFP
antibody. With GBP1+6-Fc, however, our single-molecule imaging method was still able to
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Fig 4. Binding of heterodimeric GBP antibody to EGFP. (A) Biacore surface plasmon resonance assay
for effective affinity. Three test antibodies contained a GBP6-Fc fusion with an irrelevant Fc control arm (crtl
+GBP6), a GBP1-Fc with an irrelevant Fc (crtl+GBP1), and a heterodimeric GBP1+GBP6 Fc fusion (GBP1
+GBP6). Different concentrations of recombinant EGFP, ranging from 0 to 10 nM, were injected over
immobilized Fc fusion proteins. Representative traces are in S2 Fig; rate constants in S1 Table. (B) CHO
cells expressing EGFP assessed with EGFP fluorescence or anti-EGFP immunocytochemistry. CHO cells
were transfected with EGFP fused to the transmembrane protein TMC1 as a carrier. Left panels show
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pull down EGFR, while the anti-GFP antibody could not (data not shown). Through a step-
wise photobleaching-based analysis described previously [11], we showed that about 20% of
EGFR was dimeric in the absence of ligand, indicating that dimerization is not due to receptor
over-expression.
Discussion
We have described a simple, practical approach to generate engineered antibodies with
increased affinity and specificity. In the reagents described here, the two epitopes are covalently
bound (as tandem tags or epitopes in different part of the same protein) and the two EBDs are
covalently bound (through disulfide bonds on the Fc domains) to enhance binding and create
very high affinity. Bi-specific antibodies are not new, yet they have generally been used to bind
to two separate epitopes that are on different proteins or cells, in order to bring them together.
Here, they produce high affinity for a single protein. The resulting antigen/antibody systems
have greatly improved affinity, specificity and versatility.
Dimerizing EBDs with Fc’s has several advantages in addition to avidity: Fc fusion proteins
can be recombinantly expressed, with good protein yield and solubility. Also, the Fc fragment
is a convenient handle, which enables signal amplification (through secondary antibodies), and
chemical conjugation (to fluorophores, magnetic beads, gold particles, surface immobilization,
etc) [14]. Finally, by using Fc fragments from different IgG classes and different species, a vari-
ety of reagents with the same EBDs can be generated, enabling great flexibility in imaging
experiments where multiple components are studied.
To our knowledge, the anti-THAP is by far the smallest (65 kD) anti-tag antibody with
highest affinity (70–100 pM) to the corresponding peptide tag. Other commonly used anti-tag
antibodies have lower affinity, such as the anti-HA antibody (clone 2–2.2.14, effective dissocia-
tion constant 4.5 nM), anti-Flag antibody (clone M2, 6.5 nM) [28], anti-myc antibody (clone
9E10, 80 nM) [29], or anti-His antibody (Qiagen 34440, 3.0–7.5 nM) [30]. It also has excellent
stability: since BTX is resistant to boiling and strong acids, the stability of anti-THAP—a fusion
of BTX and Fc—is determined by the stability of the IgG Fc portion.
Obviously this approach could be used to generate tandem epitopes for existing antibodies,
such as anti-HA or anti-Flag; indeed, such epitopes are often expressed as multiples. To maxi-
mize affinity, the epitopes should be separated by a flexible linker, and linker length should be
optimized. The anti-THAP reagent is smaller and more thermostable, however, and—as a
recombinant protein—more reproducible.
The heteromeric, bi-specific Fc fusion protein with two nanobodies represents a simple and
general approach to engineering high-affinity recombinant antibodies. Since nanobodies are
small (12–15 kD), multiple nanobodies can bind to the same protein without interfering with
each other. In the case of EGFP, a 27 kD globular protein, two nanobodies can bind to it
intrinsic EGFP fluorescence; right panels show label with either stock rabbit anti-GFP (top) or GBP1+6-Fc
(bottom) with appropriate secondary antibodies. Imaging of the native EGFP fluorescence revealed bright
EGFP-expressing cells, but also autofluorescence of non-transfected cells (top left). An anti-GFP antibody
signal, adjusted for the same brightness, had less but not zero non-specific signal (top right). In comparison,
the GBP1+6-Fc antibody, adjusted for the same brightness, had no detectable nonspecific label (bottom
right). (C) Direct comparison of rabbit anti-GFP and GBP1+6-Fc. Cells expressing TMC1_EGFP were
labeled with both rabbit anti-GFP and GBP1+6-Fc and with appropriate secondary antibodies of different
colors, adjusted for equal brightness. Both labeled two strongly-expressing cells (upper part of field) and two
weakly-expressing cells (middle, *), but the anti-GFP showed more nonspecific label—visible in the nuclei of
the middle cells and in a non-expressing cell (bottom, #). (D) Single-molecule pull-down. Cell lysates
containing tagged monomeric YFP were applied to slides coated with anti-HA (control), anti-GFP, or GBP1
+6-Fc. The dashed box shows the optimal range for single-molecule pull-down analysis; GBP1+6-Fc is
substantially better than anti-GFP in this range.
doi:10.1371/journal.pone.0150125.g004
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simultaneously. Since many proteins are bigger and contain multiple structural domains, and
since nanobodies generally have higher affinity and specificity than conventional antibodies,
engineered antibodies containing multiple nanobodies (targeting different parts of the same
protein) could easily be generated. These engineered antibodies should have much better affin-
ity and specificity.
Supporting Information
S1 Fig. Surface plasmon resonance traces for BTX/HAP antibody/epitope pairs. Represen-
tative data for Fig 3E. CM5 sensor chips were coupled with goat anti-human IgG. Then human
Fc fusion proteins containing either one BTX (BTX+control) or two BTX (BTX+BTX) were
bound to the chip surface through the human Fc/goat anti-human IgG interaction. To measure
affinity, solutions containing concentrations of each of the peptides (HAP, THAP_10,
THAP_14), ranging from 0 to 10 nM, were injected over immobilized Fc fusion proteins.
(PDF)
S2 Fig. Surface plasmon resonance traces for GBP/GFP antibody/target pairs. Representa-
tive data for Fig 4A. CM5 sensor chips were coupled with goat anti-human IgG. Then human
Fc fusion proteins containing either GBP1, GBP6, or both were bound to the chip surface
through the human Fc/goat anti-human IgG interaction. To measure affinity, solutions con-
taining concentrations of recombinant EGFP, ranging from 0 to 10 nM, were injected over
immobilized Fc fusion proteins.
(PDF)
S3 Fig. Full gel of Fig 3B. Immunoblot of cell extracts showing much stronger binding to the
tandem epitope with longer linker. Lysates from HEK cells expressing PCDH15 with different
tags were run on two identical gels; one was probed with the divalent C11L34 anti-GCN at a
fixed concentration and one with anti-PCDH15 as a loading control. Boxes indicate regions
shown in Fig 3B.
(PDF)
S4 Fig. Full gel of Fig 3D. Immunoblot of cell extracts showing much stronger binding to the
tandem HAP (THAP) epitope than to the single HAP. Lysates from HEK cells expressing
PCDH15 with different tags were run on two identical gels; one was probed with anti-THAP at
a fixed concentration and one with anti-PCDH15 as a loading control. Boxes indicate regions
shown in Fig 3D.
(PDF)
S1 Table. On rates, off rates and avidities for antibody/ epitope pairs based on surface plas-
mon resonance. SPR traces were analyzed using BIAevaluation 4.1 software, which calculated
rates and Kd of each interaction pair.
(PDF)
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